# Genetic Testing in Guiding Treatment for Patients With Brain Metastases

> **NCT03994796** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 50 (actual)

## Conditions studied

- CDK Gene Mutation
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Malignant Solid Neoplasm
- NTRK Family Gene Mutation
- PI3K Gene Mutation
- ROS1 Gene Mutation
- KRAS G12C Mutation

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** PI3K Inhibitor paxalisib
- **DRUG:** Entrectinib
- **DRUG:** Adagrasib

## Key facts

- **NCT ID:** NCT03994796
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-17
- **Primary completion:** 2026-10
- **Final completion:** 2028-06
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03994796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03994796, "Genetic Testing in Guiding Treatment for Patients With Brain Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03994796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*